Prophylactic hepatitis B vaccination: Present and future;Vaccination prophylactique contre l'hepatite B: Actualite et avenir

Gastroenterologie Clinique et Biologique

Volumn 23, Issue 4, 1999, Pages 452-463

  Momméja Marin, Hervé ^a   Zylberberg, Hervé ^a   Pol, Stanislas ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Escape mutant; Hepatitis B; Non responders; Vaccinal strategy; Vaccination

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; INTERLEUKIN 2; VIRUS VACCINE;

ADVERSE DRUG REACTION; DRUG SAFETY; ENDEMIC DISEASE; FEMALE; HEPATITIS B; HUMAN; IMMUNOGENICITY; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PATIENT SELECTION; PRACTICE GUIDELINE; REVIEW; SCREENING TEST; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT FAILURE; TREATMENT OUTCOME; VACCINATION; HEALTH CARE COST; RISK FACTOR;

ENDEMIC DISEASES; HEALTH CARE COSTS; HEPATITIS B; HUMANS; RISK FACTORS; VIRAL VACCINES;

EID: 0033109869     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Global adversory group. Plan of action for hepatitis B control. 16th meeting WHO, Washington DC, 1993.
2. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337: 1733-45.
3. Szmuness W, Stevens CE, Harley EJ, Zang EA, Alter HJ, Taylor PE, et al. Hepatitis B vaccine in medical staff of hemodialysis units. N Engl J Med 1982;307:1481-6.
4. Budkowska A, Dubreuil P, Poynard T, Marcellin P, Loriot MA, Maillard P, Pillot J. Anti-pre-S responses and viral clearance in chronic hepatitis B virus infection. Hepatology 1992;15:26-31.
5. Honorati MC, Dolzani P, Mariani E, Piancentini A, Lisignoli G, Ferrarri C, Facchini A. Epitope specificity of Th0/Th2 CD4+ T-lymphocyte clones induced by vaccination with rHBsAg vaccine. Gastroenterology 1997;112:2017-27.
6. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997;336:196-204.
7. Tron F, Degos F, Bréchot C, Couroucé AM, Goudeau A, Marie FN, et al. Randomized dose range study of a recombinant hepatitis B vaccine produced in mammalian cells and containing the S and preS2 sequences. J Infect Dis 1989;160:199-204.
8. Pillot J, Poynard T, Elias A, Maillard J, Lazizi Y, Brancer M, et al. Weak immunogenicity of the pre-S2 sequence and lack of circonventing effect on unresponsiveness to the hepatitis B virus vaccine. Vaccine 1995;13:289-94.
9. Ambrosch F, Kremsner P, Wiedermann G, Frisch-Niggemeyer W, Kunz C, Andre FE, Safary A. Boosting properties of recombinant DNA hepatitis B vaccine. Lancet 1986;2:1101.
10. Milich DR, McLachlan A, Chisari FV, Kent SBH, Thornton GB. Immune response to the pre-S (1) region of the hepatitis B Surface antigen (HBsAg): a pre-S(1)-specific T cell response can bypass nonresponsiveness to the pre-S(2) and S regions of HBsAg. J Immunol 1986;137:315-22.
11. Yap I, Guan R, Chan SH. Study on the comparative immunogenicity of a recombinant DNA hepatitis B vaccine containing pre-S components of the HBV coat protein with non pre-S containing vaccines. J Gastroenterol Hepatol 1995;10:51-5.
12. Chow YH, Huang WL, Chi WK, Chu YD, Tao MH. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J Virol 1997;71:169-78.
13. Davis HL, Michel ML, Whalen RG. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antiboby. Hum Mol Genet 1993;2:1847-51.
14. Koziel MJ, Liang TJ. DNA vaccines and viral hepatitis: are we going around in circles ? Gastroenterology 1997;112:1410-4.
15. Geissler M, Tokushige K, Chante CC, Zurawski VR, Jr, Wands JR. Cellular and humoral immune response to hepatitis B virus structural proteins in mice after DNA-based immunization. Gastroenterology 1997;112:1307-20.
16. Haywood AM. Transmissible spongiform encephalopathies. N Engl J Med 1998;25:1821-8.
17. Cheeseman SH, Davaro RE, Ellison III RT. Hepatitis B vaccination and plasma HIV-1 RNA. N Engl J Med 1996;5:1272.
18. Jacobson IM, Jaffers G, Dienstag JL, Tolkoff-Rubin NE, Cosimi AB, Delmonico F, et al. Immunogenicity of hepatitis B vaccine in renal transplant recipients. Transplantation 1985;39:393-5.
19. Pol S, Nalpas B, Legendre C, Kreis H. Effects of interleukin-2 on hepatitis B vaccination in uraemic patients. Lancet, 1994;344: 1369.
20. Matsaniotis N, Kattamis C, Laskari S, Tzeti M, Markosoglou D. When should at-risk patients with thalassaemia be boosted with hepatitis B vaccine ? Lancet 1987;1:1321.
21. Hadler SC, Francis DP, Maynard JE, Thompson SE, Judson FN, Echenberg DF, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986;315:209-14.
22. Coursaget P, Yvonnet B, Gilks WR, Wang CC, Day NE, Chiron JP, Diop-Mar I. Scheduling of revaccination against hepatitis B virus. Lancet 1991;337:1180-3.
23. Mannucci PM, Zanetti AR, Gringeri A, Tanzi E, Morfini M, Messori A, et al. Long term immunogenicity of a plasma-derived hepatitis B vaccine in HIV seropositive and HIV seronegative hemophiliacs. Arch Intern Med 1989;149:1333-7.
24. Nommensen FE, Go ST, MacLaren DM. Half-live of HBs antibody after hepatitis B vaccination: an aid to timing of booster vaccination. Lancet 1989;2:847-9.
25. Struve J, Aronsson B, Frenning B, Granath F, Von Sydow M, Weiland O. Intramuscular versus intradermal administration of a recombinant hepatitis B vaccine: a comparison of response rates and analysis of factors influencing the antibody response. Scand J Infect Dis 1992;24:423-9.
26. Bryan JP, Sjogren MH, Perine PL, Legters LJ. Low-dose intradermal and intramuscular vaccination against hepatitis B. Clin Infect Dis 1992;14:697-707.
27. Goudeau A. L'hépatite B. (plaquette) Paris : Institut Pasteur Productions.
28. Lok ASF, Lai CL, Wu PC. Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: implications in hepatitis B vaccination programs. Hepatology 1988;8:766-70.
29. Werner BG, Dienstag JL, Kuter BJ, Polk BF, Snydman DR, Craven DE, et al. Isolated antibody to hepatitis B surface antigen and response to hepatitis B vaccination. Ann Intern Med 1985;103:201-5.
30. Dienstag JL, Stevens CE, Bhan AK, Szmuness W. Hepatitis B vaccine administered to chronic carriers of hepatitis B surface antigen. Ann Intern Med 1982;96:575-9.
31. Article L 10 du code de la santé publique. Journal Officiel de République Française, 21 décembre 1991:2618.
32. Arrété du 15 mars 1991 fixant la liste des établissements ou organismes publics ou privés de prévention ou de soin dans lesquels le personnel exposé doit être vacciné. Journal Officiel de République Française, 3 avril 1991:4464-5.
33. Cooperative. Immunisation against hepatitis B. Lancet 1988;1: 875-6.
34. McLean AA, Hilleman MR, McAleer WJ, Buynak EB. Summary of world-wide experience with H-B-vax (B. MSD). J Infect 1983;7:95-104.
35. Lybecker LA, Mendenhall CL, Marshall LE, Weesner RE, Myre SA. Response to hepatitis B vaccine (Hbvac) in the alcoholic (abstract). Hepatology 1983;3:807
36. Wood RC, MacDonald KL, White KE, Hedberg CW, Hanson M, Osterholm MT. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA 1993;270:2935-9.
37. Varla-Leftherioti M, Papanicolaou M, Spyropoulou M, Vallindra H, Tsiroyianni P, Tassopuolos N, et al. HLA-associated non-responsiveness to Hepatitis B vaccine. Tissue Antigens 1990;35: 60-3.
38. Craven DE, Awdeh ZL, Kunches LM, Yunis EJ, Dienstag JL, Werner BG, et al. Nonresponsiveness to hepatitis B vaccine in health care workers, results of revaccination and genetic typings. Ann Intern Med 1986;105:356-60.
39. Alper CA, Kruskall MS, Marcus-Bagley D, Craven DE, Katz AJ, Brink SJ, et al. Genetic predisposition of nonresponse to hepatitis B vaccine. N Engl J Med 1989;321:708-12.
40. Crosnier J, Jungers P, Couroucé AM, Laplanche A, Benhamou E, Degos F, et al. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in french haemodialysis units: II, haemodialysis patients. Lancet 1981;1:797-800.
41. Köhler H, Arnold W, Renschin G, Dormeyer HH, Meyer zum Büschenfelde KH. Active hepatitis B vaccination of dialysis patients and medical staff. Kidney Int 1984;25:124-8.
42. Drachman R, Isacsohn M, Rudensky B, Drukker A. Vaccination against hepatitis B in children and adolescent patients on dialysis. Nephrol Dial Transplant 1989;4:372-4.
43. Carne CA, Weller IVD, Waite J, Briggs M, Pearce F, Adler MW, Tedder RS. Impaired responsiveness of homosexual men with HIV antibodies to plasma derived hepatitis B vaccine. Br Med J 1987;294:866-8.
44. Collier AC, Corey L, Murphy VL, Handsfield HH. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann Intern Med 1988;109:101-5.
45. Degos F, Duhamel G, Bréchot C, Nalpas B, Courouce AM, Tron F, et al. Hepatitis B vaccination in chronic alcoholics. J Hepatol 1986;2:402-9.
46. Pol S, Legendre C, Mattlinger B, Berthelot P, Kreis H. Genetic basis of nonresponse to hepatitis B vaccine in hemodialyzed patients. J Hepatol 1990;11:385-7.
47. Maggiolo DTF, Broggini M, Botta V. Skin testing to predict immune response to hepatitis B vaccine. Lancet 1985;1:783-4.
48. Benhamou E, Courouce AM, Jungers P, Laplanche A, Degos F, Brangier J, et al. Hepatitis B vaccine: randomized trial of immunogenicity in hemodialysis patients. Clin Nephrol 1984;21: 143-7.
49. Nalpas B, Thepot V, Driss F, Pol S, Courouce AM, Saliou P, et al. Secondary immune response to hepatitis B virus vaccine in alcoholics. Alcohol Clin Exp Res 1993;17:295-8.
50. Nagafuchi S, Kashiwagi S, Okada K, Anzai K, Nakamura M, Nishimura Y, et al. Reversal of nonresponders and postexposure prophylaxis by intradermal hepatitis B vaccination in japanese medical personnel. JAMA 1991;265:2679-83.
51. Quiroga JA, Castillo I, Porres JC, Casado S, Saez F, Martinez MG, et al. Recombinant gamma-interferon as adjuvant to hepatitis B vaccine in hemodialysis patients. Hepatology 1990;12:661-3.
52. Meuer SC, Dumann H, Meyer zum Büschenfelde KH, Köhler H. Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination. Lancet 1989;1:15-7.
53. Jungers P, Devillier P, Salomon H, Cerisier J E, Courouce AM. Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine. Lancet 1994;344:856-7.
54. Maupas P, Chiron JP, Barin F, Coursaget P, Goudeau A, Perrin J, et al. Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children. Controlled trial in an endemic area (Senegal). Lancet 1981;1:289-92.
55. Poovorawan Y, Sanpavat S, Pongpunlert W, Chumdermpadetsuk S, Sentrakul P, Safary A. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. JAMA 1989;261:3278-81.
56. Desmyter J, Colaert J, De Groote G, Reynders M, Reerink-Brongers EE, Lelie PN, et al. Efficacy of heat-inactivated hepatitis B vaccine in haemodialysis patients and staff. Double-blind placebo-controlled trial. Lancet 1983;1:1323-8.
57. Seeff LB, Koff RS. Passive and active immunoprophylaxis of hepatitis B. Gastroenterology 1984;86:958-81.
58. Mitsui T, Iwano K, Suzuki S, Yamazaki C, Masuko K, Tsuda F, et al. Combined hepatitis B immune globulin and vaccine for post exposure prophylaxis of accidental hepatitis B virus infection in hemodialysis staff members: comparison with immune globulin without vaccine in historical controls. Hepatology 1989;10:324-7.
59. Goh KT. Hepatitis B immunisation in Singapore. Lancet 1996;348:1385-6.
60. Grosheide P, Van Damme P. Viral hepatitis: action on hepatitis B as a community health risk. In: Viral Hepatitis Prevention Board eds. Prevention and control of hepatitis B in the community. Edegem, Belgium: Jacqmain 1996;2:2-11.
61. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997;336: 1855-9.
62. Senejoux A, Roulot D, Belin C, Tsakiris L, Rautureau J, Coste T. Myélite aigüe après immunisation contre l'hépatite B par un vaccin recombinant. Gastroenterol Clin Biol 1996;20:401-2.
63. Herroelen L, De Keyser J, Ebinger G. Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine. Lancet 1991;338:1174-5.
64. Anonymous. Expanded programme on immunization (EPI). Lack of evidence that hepatitis B vaccine causes multiple sclerosis. Weekly Epidemiol Record 72:149-52.
65. Cambier J, Masson M, Dehen H, eds. Abrégé de Neurologie. Paris : Masson, 1989:303-22.
66. Allen MB, Cockwell P, Page RL. Pulmonary and cutaneous vasculitis following hepatitis B vaccination. Thorax 1993;48: 580-1.
67. Mathieu E, Fain O, Krivitzky A. Cryoglobulinemia after hepatitis B vaccination. Lancet 1995;5:355.
68. Fried M, Conen D, Conzelmann M, Steinemann E. Uveitis after hepatitis B vaccination. Lancet 1987;2:631-2.
69. Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990;336:325-9.
70. Zanetti AR, Tanzi E, Harrison TJ, Manzillo G, Zuckermann AJ. Hepatitis B virus escape mutants. Meeting on Genetic Heterogeneity of Hepatitis Viruses, Sestrière, 1991.
71. Whittle HC, Inskip H, Hall AJ, Mendy M, Downes R, Hoare S. Vaccination against hepatitis B and protection against chronic viral carriage in the Gambia. Lancet 1991;337:747-50.
72. McMahon G, McCarthy LA, Dottavio D, Ostberg L. Surface antigen and polymerase gene variation in hepatitis B virus isolates from a monoclonal antibody treated liver transplant patient. In: Hollinger B, Lemon S, Margolis B, eds. Viral hepatitis and liver disease. New York: Alan Liss, 1991:216-9.
73. Carman WF, Thomas HC. Genetic variation in hepatitis B virus. Gastroenterology 1992;102:711-9.
74. Waters JA, Kennedy M, Voet P, Hauser P, Petre J, Carman W, Thomas HC, et al. Loss of commun « A »determinant of hepatitis B surface antigen by a vaccine induced escape mutant. J Clin Invest 1992;90:2543-7.
75. Kerleau M, Flori YA, Nalpas B, Lanoé JL, Berthelot P, Fardeau-Gauthier M. Analyse coût-efficacité d'une politique de prévention vaccinale de l'hépatite virale B. Med Sci 1995;11: 1474-7.
76. Kane MA. Global status of hepatitis B immunisation. Lancet 1996;348:696.
77. Squarcione S, Pompa MG, Vellucci L. Morbidity from hepatitis B after introduction of nationwide immunisation in Italy. Lancet 1997;350:114.
78. Davidson M, Krugman S. Recombinant yeast hepatitis B vaccine compared with plasma-derived vaccine: immunogenicity and effect of a booster dose. J Infect 1986;13:31-8.
79. Lee CY, Hwang LY, Beasley RP. Low-dose hepatitis B vaccine. Lancet 1989;2:860-1.
80. Laboratoires SmithKline Beecham, unité vaccin. Observatoire de la vaccination contre l'hépatite B. Le bilan de la vaccination au 31 décembre 1996. SOFRES médical/SB.